Patents Assigned to Hadasit Medical Research Services and Development Ltd.
  • Publication number: 20170105996
    Abstract: Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering front type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
    Type: Application
    Filed: October 14, 2016
    Publication date: April 20, 2017
    Applicants: Teva Pharmaceutical Industries, Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Yaron ILAN, Doina Cosma ROMAN, Michael HAYDEN, Einat AMIT-ROMACH
  • Patent number: 9616067
    Abstract: The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisinin derivatives having anti-viral activity.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: April 11, 2017
    Assignees: Hadasit Medical Research Services and Development Ltd., The Hong Kong University of Science and Technology
    Inventors: Richard K. Haynes, Dana G. Wolf
  • Publication number: 20170071952
    Abstract: The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisinin derivatives having anti-viral activity.
    Type: Application
    Filed: November 25, 2016
    Publication date: March 16, 2017
    Applicants: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Richard K. HAYNES, Dana G. WOLF
  • Publication number: 20160333072
    Abstract: Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
    Type: Application
    Filed: January 8, 2015
    Publication date: November 17, 2016
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Abraham RUTENBERG, Ronny UZANA, Michal LOTEM, Arthur MACHLENKIN, Galit EISENBERG, Tamar PERETZ-YABLONSKY, Shoshana FRANKENBURG, Roni ENGELSTEIN
  • Publication number: 20160333344
    Abstract: Provided is a miR-122* as a functional microRNA molecule, compositions including the same and uses thereof for treatment of various conditions, such as, cancer.
    Type: Application
    Filed: January 6, 2015
    Publication date: November 17, 2016
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Hilla GILADI, Alina SIMERZIN, Yael HANTZ, Sagit ARBEL ALON, Eithan GALUN
  • Publication number: 20160317570
    Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
    Type: Application
    Filed: July 10, 2016
    Publication date: November 3, 2016
    Applicants: Hadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Yaron ILAN, Gadi LALAZAR, Eyal SHTEYER, Ami BEN-YA'ACOV, Smadar COHEN, Tsiona ELKAYAM
  • Patent number: 9474763
    Abstract: Pharmaceutical compositions including combinations of protective agents selected from isosilybin B, methylsulfonylmethane (MSM), phosphatidylcholine, cysteine (Cys), seleno-cysteine (Se-Cys), ribose-cysteine (RibCys), N-acetylcysteine (NAC), N-acetylcysteine-amide (AD4), methionine (Met) and S-adenosylmethionine (SAM) for reducing and/or preventing drug-induced toxicity, such as acetaminophen-induced toxicity. The compositions may be formulated with or without acetaminophen, and accordingly may be used as safe formulations of acetaminophen with reduced risk of causing liver damage, or as an antidote for the treatment of acetaminophen overdose. Methods for treating acetaminophen intoxication.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: October 25, 2016
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Josef Mograbi, Yaron Ilan
  • Patent number: 9469855
    Abstract: The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: October 18, 2016
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rifaat Safadi
  • Patent number: 9387222
    Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
    Type: Grant
    Filed: November 27, 2008
    Date of Patent: July 12, 2016
    Assignees: Hadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Yaron Ilan, Gadi Lalazar, Eyal Shteyer, Ami Ben-Yaakov, Smadar Cohen, Tsiona Elkayam
  • Publication number: 20160175416
    Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
    Type: Application
    Filed: February 23, 2016
    Publication date: June 23, 2016
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Tamar PERETZ, Michal LOTEM, Arthur MACHLENKIN, Shoshana FRANKENBURG, Inna BEN DAVID, Anna KUZNETZ, Yael GELFAND, Galit EISENBERG, Merav DARASH YAHANA
  • Patent number: 9358307
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Grant
    Filed: January 25, 2009
    Date of Patent: June 7, 2016
    Assignees: GAVISH-GALILEE BIO APPLICATIONS LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
  • Publication number: 20160143816
    Abstract: Ostomy tubes, particularly gastrostomy tubes, with improved retention means are provided. More specifically, retention structures, such as bolsters, for gastrostomy tubes are provided, configured to removably assemble to one end of a gastrostomy tube to facilitate replacement and removal of the tube. The retention structures provided herein may comprise one or more removably assembled retention elements. Further provided are gastrostomy tubes comprising such retention structures, and methods for percutaneous endoscopic gastrostomy utilizing same.
    Type: Application
    Filed: June 19, 2014
    Publication date: May 26, 2016
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventor: Ishay BENURI-SILBIGER
  • Patent number: 9301998
    Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: April 5, 2016
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Tamar Peretz, Michal Lotem, Arthur Machlenkin, Shoshana Frankenburg, Inna Ben David, Anna Kuznetz, Yael Gelfand, Galit Eisenberg, Merav Darash Yahana
  • Patent number: 9297804
    Abstract: The invention is directed to separation of amylase from body fluid by contacting said body fluid with starch under conditions enabling binding between the amylase and the starch, separating between the starch-amylase bound complexes and the free components, thereby removing the bound amylase, and collecting the non-bound components.
    Type: Grant
    Filed: May 1, 2008
    Date of Patent: March 29, 2016
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Aaron Palmon, Omer Doitch, Doron Aframian
  • Patent number: 9243294
    Abstract: The present invention provides a method of treating, attenuating or preventing a liver disorder by inhibiting NLGn4 expression and thereby modulating the activity of NK cells. The present invention further relates to diagnosing a liver disorder by evaluating NLGn4 expression in NK cells.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 26, 2016
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rifaat Safadi
  • Patent number: 9155595
    Abstract: The present invention provides a selective coating of an endodontic file, in which the distal end of the file is uncoated or alternatively leaving the outermost part of the blades of the distal end portion uncoated. The distribution of the nanoparticles is thus non uniform along the surface of the file leaving only a part of the file coated. In the present invention, the distal end of the device being subjected to the highest torque is either uncoated at all, or has a coated core and uncoated blades.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: October 13, 2015
    Assignees: YEDA RESEARCH AND DEVELOPMENT CO. LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Reshef Tenne, Meir Redlich, Adi Ram-Adini, Yishay Feldman, Gili Naveh, Joshua Moshonov, Boaz Shay
  • Patent number: 9072737
    Abstract: The invention relates to tPA mutant devoid of protease activity and uses thereof in compositions and methods for the treatment and prevention of pathologic conditions involving neurological injury or an ischemic disease or condition. More specifically, the invention relates to a Ser481 to Ala mutant of tPA and to compositions and combinations thereof for the treatment of stroke, acute brain injury and neurodegenerative disorders. The invention further provides methods and kits for the treatment of said disorders.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: July 7, 2015
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Abd Higazi, Nuha Hijazi
  • Patent number: 9034814
    Abstract: The present invention provides novel uses for CXCR4 antagonists, including specifically peptides of the T-140 family, in the treatment of skin burns and other injuries. The invention further provides methods for increasing epithelialization in a subject in need thereof, and for preventing or inhibiting fibrosis and excessive scar formation, using peptide inhibitors of the T-140 family as well as other CXCR4 antagonists.
    Type: Grant
    Filed: May 21, 2006
    Date of Patent: May 19, 2015
    Assignees: Hadasit Medical Research Services and Development Ltd., Kyoto University
    Inventors: Amnon Peled, Nobutaka Fujii
  • Publication number: 20150125506
    Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGF? superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGF? superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.
    Type: Application
    Filed: December 29, 2014
    Publication date: May 7, 2015
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Masha IDELSON, Ruslana ALPER-PINUS, Alex OBOLENSKY, Eyal BANIN, Benjamin Eithan REUBINOFF
  • Publication number: 20150118749
    Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGF? superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGF? superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.
    Type: Application
    Filed: December 29, 2014
    Publication date: April 30, 2015
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Masha IDELSON, Ruslana ALPER-PINUS, Alex OBOLENSKY, Eyal BANIN, Benjamin Eithan REUBINOFF